Atea Pharmaceuticals (AVIR) Earnings Date, Estimates & Call Transcripts $2.90 +0.01 (+0.17%) As of 11:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Atea Pharmaceuticals Earnings Summary Atea Pharmaceuticals posted Q1 2025 earnings on May 12, 2025, reporting an EPS of -$0.40, which topped analysts' consensus estimates of -$0.56 by $0.16. With a trailing EPS of -$1.65, Atea Pharmaceuticals' earnings are expected to grow next year, from ($2.01) to ($1.79) per share. Upcoming Q2 Earnings DateAug. 6After Market ClosesEstimatedConsensus EPS (May. 12) -$0.56 Actual EPS (May. 12) -$0.40 Beat By $0.16 Q1 2025 Earnings ResourcesQ1 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)AVIR Upcoming EarningsAtea Pharmaceuticals' next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules. Powered by Get Atea Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atea Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataAVIR Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Atea Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.48-$0.48-$0.48Q2 20251-$0.45-$0.45-$0.45Q3 20251-$1.50-$1.50-$1.50Q4 20251-$0.47-$0.47-$0.47 FY 2025 4 -$2.90 -$2.90 -$2.90 Q1 20261-$0.47-$0.47-$0.47Q2 20261-$0.46-$0.46-$0.46Q3 20261-$0.46-$0.46-$0.46Q4 20261-$0.46-$0.46-$0.46 Atea Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/6/2025(Estimated)--------5/12/2025Q1 2025-$0.56-$0.40+$0.16-$0.40--3/6/2025Q4 2024-$0.35-$0.40 -$0.05-$0.40--11/7/2024Q3 2024-$0.50-$0.37+$0.13-$0.37--8/7/2024Q2 2024-$0.76-$0.48+$0.28-$0.48--5/14/2024Q1 2024-$0.61-$0.75 -$0.14-$0.75--2/28/2024Q4 2023-$0.44-$0.47 -$0.03-$0.47--11/8/2023Q3 2023-$0.46-$0.40+$0.06-$0.40--8/8/2023Q2 2023-$0.47-$0.34+$0.13-$0.34-- Atea Pharmaceuticals Earnings - Frequently Asked Questions When is Atea Pharmaceuticals's earnings date? Atea Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 6th, 2025 based off last year's report dates. Learn more on AVIR's earnings history. Did Atea Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Atea Pharmaceuticals (NASDAQ:AVIR) reported ($0.40) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.56) by $0.16. Learn more on analysts' earnings estimate vs. AVIR's actual earnings. How much profit does Atea Pharmaceuticals generate each year? Atea Pharmaceuticals (NASDAQ:AVIR) has a recorded net income of -$135.96 million. AVIR has generated -$1.65 earnings per share over the last four quarters. What is Atea Pharmaceuticals's EPS forecast for next year? Atea Pharmaceuticals's earnings are expected to grow from ($2.01) per share to ($1.79) per share in the next year. More Earnings Resources from MarketBeat Related Companies Phibro Animal Health Earnings Date Mineralys Therapeutics Earnings Date Collegium Pharmaceutical Earnings Date Syndax Pharmaceuticals Earnings Date Arcus Biosciences Earnings Date Enliven Therapeutics Earnings Date Avadel Pharmaceuticals Earnings Date Spyre Therapeutics Earnings Date Intellia Therapeutics Earnings Date Pharvaris Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds This page (NASDAQ:AVIR) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
